Data showcased in session titled “Spotlight on Drug Delivery” at the Ophthalmology Innovation Source (OIS) Retina 8th Annual Innovation Summit -VLTR-559, a long-acting anti-VEGF therapy, could reduce ...

EyePoint Pharmaceuticals has concluded subject enrolment in the pivotal Phase III programme assessing Duravyu, aimed at ...

On July 17, 2025, Harrow, Inc. (“Harrow”), announced an agreement with Samsung Bioepis Co. Ltd. (“Samsung Bioepis”) to acquire the U.S.

Faricimab, compared with aflibercept, reduces the risk of epiretinal membrane formation in eyes with diabetic macular edema, research shows.

Lightbridge Corporation ('Lightbridge” or the 'Company”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, will ...